OSTX - OS Therapies

-

$undefined

N/A

(N/A)

OS Therapies NYSE American:OSTX OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Grasonville, Maryland.

Location: 115 Pullman Crossing Road, Grasonville, MD, 21638, United States | Website: https://ostherapies.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

46.22M

Cash

2.971M

Avg Qtr Burn

-2.521M

Short % of Float

1.38%

Insider Ownership

33.38%

Institutional Own.

1.39%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
OST-HER2 Details
Recurrent, fully resected, lung metastatic pediatric osteosarcoma

Phase 2

Data readout